Share chart VYNE Therapeutics Inc.
Extended chart
Simple chart
About VYNE Therapeutics Inc.
Фармацевтическая компания VYNE Therapeutics Inc. специализируется на разработке и коммерциализации различных терапевтических средств для дерматологии. Он предлагает AMZEEQ, миноциклин для местного применения, используемый для лечения воспалительных поражений неузловых среднетяжелых и тяжелых вульгарных угрей у пациентов в возрасте 9 лет и старше. more detailsMain settings
IPO date
2018-01-25
ISIN
US92941V2097
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Див.доход ао
0
Сайт
Grade
Underestimation
| Title | Value | Grade |
| P/S | 271.18 | 1 |
| P/BV | 2.61 | 6 |
| P/E | 2.79 | 10 |
Efficiency
| Title | Value | Grade |
| ROA | -48.4 | 0 |
| ROE | -56.57 | 0 |
| ROIC | -111.75 | 0 |
Dividends
| Title | Value | Grade |
| Dividend yield | 0 | 0 |
| DSI | 0 | 0 |
| Average dividend growth | 0 | 0 |
Debt
| Title | Value | Grade |
| Debt/EBITDA | -0.0023 | 10 |
| Debt/Ratio | 0.0015 | 10 |
| Debt/Equity | 0.2845 | 10 |
Growth impulse
| Title | Value | Grade |
| Yield Revenue, % | -97.61 | 0 |
| Yield Ebitda, % | -61.04 | 0 |
| Yield EPS, % | -99.34 | 0 |
Prices
| Price | Min. | Max. | Change | Changes in the industry | Changes in the index | |
| Yesterday | 1.04 $ | 0 $ | 0 $ | 0 % | 0 % | 0 % |
| Week | 1.22 $ | 0 $ | 0 $ | -14.75 % | 0 % | 0 % |
| Month | 1.88 $ | 1 $ | 1.26 $ | -44.68 % | 0 % | 0 % |
| Three month | 2.8 $ | 1 $ | 1.88 $ | -62.86 % | 0 % | 0 % |
| Half a year | 2.89 $ | 1 $ | 4.28 $ | -64.01 % | 0 % | 0 % |
| Year | 2.58 $ | 1 $ | 4.28 $ | -59.69 % | 0 % | 0 % |
| 3 years | 0.4849 $ | 0.1187 $ | 72.58 $ | 114.48 % | 0 % | 0 % |
| 5 years | 33.28 $ | 0.1187 $ | 72.58 $ | -96.88 % | 0 % | 0 % |
| 10 years | 0 $ | 0.1187 $ | 601.28 $ | 0 % | 0 % | 0 % |
| Year to date | 2.56 $ | 1 $ | 4.28 $ | -59.38 % | 0 % | 0 % |
Main owners
| Institutions | Volume | Share, % |
| Eventide Asset Management LLC | 1 394 336 | 9.89 |
| Cormorant Asset Management, LP | 1 394 336 | 9.89 |
| Citadel Advisors Llc | 1 181 088 | 8.38 |
| Soleus Capital Management, L.P. | 703 868 | 4.99 |
| Parkman Healthcare Partners LLC | 696 470 | 4.94 |
| DSC Advisors, L.P. | 696 465 | 4.94 |
| AlphaCentric Advisors LLC | 668 151 | 4.74 |
| Palo Alto Investors Lp | 445 434 | 3.16 |
| Prelude Capital Management LLC | 118 100 | 0.84 |
| Exome Asset Management LLC | 118 100 | 0.84 |
Similar companies
P/E & P/BV
Company management
| Head | Job title | Payment | Year of birth |
| Mr. David T. Domzalski | CEO, President & Director | 1.61M | 1967 (58 years) |
| Mr. Tyler Zeronda | CFO & Treasurer | N/A | 1987 (38 years) |
| Ms. Mutya Harsch J.D. | General Counsel, Chief Legal Officer & Company Secretary | 817.97k | 1975 (50 years) |
| Dr. Iain A. Stuart Ph.D. | Chief Scientific Officer | 856.82k | 1973 (52 years) |
| Dr. Subhashis Banerjee M.D. | Senior Vice President of Clinical Development | ||
| Dr. Darrell S. Rigel FAAD, M.D. | Consultant | 1951 (74 years) |
About company
Address: United States, Bridgewater, 520 U.S. Highway 22 - Open in google maps, Open in yandex maps
Website: http://www.vynetherapeutics.com
Website: http://www.vynetherapeutics.com
